KRAS and HDAC1 gene mutations may be early events in the molecular pathogenic cascade that leads to PDAC and thus they are potential targets for pancreatic cancer gene therapy.[99, 100] A study used multi‐functionalized monolayer graphene oxide (GO) as a gene delivery vehicle to effectively co‐deliver HDAC1 and K‐Ras siRNAs (small interfering RNAs) targeting the HDAC1 gene and the mutant K‐Ras gene in pancreatic cancer cells MIA PaCa‐2. This evidence concerns the gene KRAS and pancreatic neoplasm.